We have constructed two new adenovirus expression cassettes that expand both the range of genes which can be expressed with adenovirus vectors (AdV) and the range of cells in which high-level expression can be attained. By inclusion of a tetracycline-regulated promoter in the transfer vector pAdTR5, it is now possible to generate recombinant adenoviruses expressing proteins that are either cytotoxic or that interfere with adenovirus replication. We have used this strategy to generate a recombinant adenovirus encoding a deletion in the R1 subunit [R1(⌬2-357)] of the herpes simplex virus type 2 ribonucleotide reductase. Cell lines expressing the tetracycline-regulated transactivator (tTA) from an integrated vector or following infection with an AdV expressing tTA are able to produce ⌬R1 protein at a level approaching 10% total cell protein (TCP) when infected with Ad5TR5⌬R1 before they subsequently die. To our knowledge, this is the first report of the overexpression of a toxic gene product with AdV. We have also constructed a new constitutive adenovirus expression cassette based on an optimized cytomegalovirus immediate-early promoter-enhancer that allows the expression of recombinant proteins at a level greater than 20% TCP in nonpermissive cell lines. Together, these new expression cassettes significantly improve the utility of the adenovirus system for high-level expression of recombinant proteins in animal cells and will undoubtedly find useful applications in gene therapy.
We have constructed two new adenovirus expression cassettes that expand both the range of genes which can be expressed with adenovirus vectors (AdV) and the range of cells in which high-level expression can be attained. By inclusion of a tetracycline-regulated promoter in the transfer vector pAdTR5, it is now possible to generate recombinant adenoviruses expressing proteins that are either cytotoxic or that interfere with adenovirus replication. We have used this strategy to generate a recombinant adenovirus encoding a deletion in the R1 subunit [R1(⌬2-357)] of the herpes simplex virus type 2 ribonucleotide reductase. Cell lines expressing the tetracycline-regulated transactivator (tTA) from an integrated vector or following infection with an AdV expressing tTA are able to produce ⌬R1 protein at a level approaching 10% total cell protein (TCP) when infected with Ad5TR5⌬R1 before they subsequently die. To our knowledge, this is the first report of the overexpression of a toxic gene product with AdV. We have also constructed a new constitutive adenovirus expression cassette based on an optimized cytomegalovirus immediate-early promoter-enhancer that allows the expression of recombinant proteins at a level greater than 20% TCP in nonpermissive cell lines. Together, these new expression cassettes significantly improve the utility of the adenovirus system for high-level expression of recombinant proteins in animal cells and will undoubtedly find useful applications in gene therapy.
The adenovirus expression system (AES) is routinely used both for protein production and for gene transfer experiments (reviewed in references 2, 4, 5, 14, 31, and 34). Among the attractive features of the AES are the high gene transfer capacity of adenovirus vectors (AdV) in a wide range of cell types both in vitro and in vivo and very efficient transgene expression. We recently reported on an adenovirus major late promoter (MLP) expression cassette, pAdBM5, which allows for the production of heterologous proteins in the human 293 cell line at levels of 15 to 20% total cell protein (TCP) (23) . Successful overexpression with pAdBM5 and with similar vectors during the course of adenovirus replication in permissive 293 cells is due both to the efficiency of the expression cassette and to gene amplification in combination with the selective expression of viral genes during the late phase of the adenovirus lytic cycle. Thus, the level of transgene expression with AdV having deletions of E1 following infection of nonpermissive cells even at a high multiplicity of infection (MOI) is much lower than that in 293 cells. For gene transfer experiments in nonpermissive cells, most AdV make use of the cytomegalovirus (CMV) immediate-early (IE) promoter-enhancer in the expression cassette, since this promoter is one of the strongest in a wide range of cell types (reviewed in references 22 and 36) . Despite this fact, AdV with CMV-based expression cassettes rarely produce protein exceeding 1 to 2% TCP after infection of either nonpermissive cells or 293 cells (1, 18, 25, 37, 38, 40) .
In addition, the utility of the AES is limited to the expression of proteins that either do not produce cytotoxic effects or interfere with AdV replication, since these situations make it impossible to generate recombinants (15) . Among the genes that we were unable to rescue into AdV using the pAdBM5 transfer vector (Ϸ5% of our attempts; unpublished data) are a series of deletion mutants of the herpes simplex virus type 2 (HSV-2) ribonucleotide reductase R1 subunit. To overcome this limitation, an ideal expression cassette should be regulated in such a way that the basal level of transgene expression is low enough to avoid any interference with adenovirus replication and yet is capable of becoming very high when fully induced. Although several inducible promoters are available, the tetracycline-controllable transactivator system is becoming the most widely used in mammalian cells in cultures (11-13, 20, 24, 27, 28) and in transgenic mice (29) . This system makes use of a trans-acting factor (tTA) formed by the fusion of the activation domain of HSV protein VP16 to the Escherichia coli tetracycline repressor protein (12) . The tTA transactivator can stimulate transcription from a promoter containing the tetracycline operator sequences (tetO) but is prevented from interacting with tetO by tetracycline concentrations that are not toxic for eukaryotic cells (reviewed in reference 11). A modified tTA (rtTA) which interacts with tetO only when certain tetracycline analogs are present has also been developed (13) .
Here, we describe pAdTR5, an AdV containing a tetracycline-regulated expression cassette that inducibly overexpresses nontoxic proteins such as the HSV-2 R1 subunit at levels as high as 20 to 25% TCP in both 293 cells and nonpermissive cells. When compared with that of our newly optimized constitutive CMV-based expression cassette, pAdCMV5, the performance of pAdTR5 was found to be roughly equivalent. Moreover, we have constructed with this controllable vector a recombinant adenovirus expressing a putatively toxic R1 protein truncated at its amino-terminal end (⌬R1). tTA-expressing cells infected with this recombinant produced, before their death, ⌬R1 at a level approaching 10% TCP. As the abrogation of ⌬R1 synthesis with anhydrotetracycline prevented cell death, we could conclude that recombinant protein expression was responsible for the death process.
MATERIALS AND METHODS

Cells and viruses.
The conditions for culturing of human 293 cells, either the original anchorage-dependent 293A line (16) or 293S, an anchorage-independent clone, were as described previously (9, 23) . HeLa S3 and A549 cells were obtained from the American Type Culture Collection and cultured with the same medium as that used for 293A cells. Ad5/⌬E1⌬E3 was used as the parent virus in our viral constructs (10) . Viruses were purified from infected cells and titers were determined by standard protocols (23) .
Construction of the transfer vectors pAdCMV5 and pAdTR5 and of recombinant adenoviruses. All recombinant DNA molecules were constructed by standard cloning and site-directed mutagenesis procedures and propagated in E. coli DH5. The transfer vector pAdCMV5 was derived from pAdCMV/(rabbit ␤-globin)-poly(A) (18) by several subcloning steps resulting in the insertion, downstream of the ϩ1 start site for the transcription of the human CMV IE promoter-enhancer, of a PCR fragment containing the adenovirus tripartite leader with the adenovirus major late enhancer bracketed by splice donor and acceptor sites, as found in pAdBM5 (23) . In the process, an additional unique 8-bp cutter cloning site (PmeI) was added before the BamHI site (Fig.  1) . pAdTR5 (tetracycline regulatable) was derived from pUHD10-3 (12) and pAdCMV5 in two steps. The same PCR fragment containing the adenovirus tripartite leader and enhancer sequences from pAdBM5 was first subcloned in pUHD10-3 downstream of the minimal CMV TATA box (P hCMV-1 ) of the tetracycline-regulated promoter. This modified tetracycline-regulated promoter was then subcloned as an AatII-BamHI fragment, blunted at the AatII site, into pAdCMV5, in place of the CMV IE promoter-enhancer, between the BglII (at map position 9.4) and BamHI sites. This was realized by blunting the BglII sites, after BglII partial digestion, followed by BamHI digestion and ligation of the insert to obtain pAdTR5 (Fig. 1) .
The construction of pAdCMV5-R1 and pAdTR5-R1 was done by subcloning the HSV-2 R1 gene as a BamHI fragment excised from pAdBM5-R1 (23). Mutant HSV-2 R1(⌬2-357) was constructed by PCR mutagenesis of the pUC13-R1 vector used to derive pAdBM5-R1. Following mutagenesis, R1 truncated at its amino-terminal end (⌬R1) was subcloned as a BamHI fragment in the adenovirus transfer vectors pAdBM5, pAdCMV5, and pAdTR5. pAdTR5-GFP was constructed by cloning a BamHI fragment amplified by PCR from the pRSET vector expressing the Aequorea victoria GFP(S65T) mutant obtained from R. Y. Tsien (University of California). The coding region of GFP(S65T) was amplified with Vent polymerase (New England BioLabs, Beverly, Mass.) by use of upstream (5Ј-CTACCGGATCCGCCGCCGCCATGAGTAAAGGAGAAGAAC T-3Ј) and downstream (5Ј-CTACCGGATCCCTAGTCACTTATTTGTATAGT TCATCCAT-3Ј) primers. To construct an AdV expressing the tTA transactivator, an XhoI-BamHI fragment from ptTA-lux, the vector used to generate stable cell lines (see below), was subcloned into an adenovirus transfer vector similar to pAdTR5. In the process, the expression cassette including the CMV promoter, the tTA-coding region, and a poly(A) site in the same configuration as that found in pUHD15-1 (12) were inserted in place of the TR5 expression cassette.
Recombinant adenoviruses were obtained by cotransfection of 293A cells with the various ClaI-restricted transfer vectors and the large right-end fragment of the Ad5/⌬E1⌬E3 genome. Digestion of Ad5/⌬E1⌬E3 viral DNA with ClaI prior to transfection allowed recombinant adenoviruses to be obtained at a frequency of 10 to 80%. The positive plaques were purified and expanded in 293 cells following the rigorous protocol detailed by Jani et al. (18) in order to minimize the occurrence of replication-competent adenoviruses. Large-scale virus stocks were prepared by infecting 3 ϫ 10 9 293S cells in suspension cultures as described previously (9, 18) , and titers were determined by a plaque assay on 293A cells and revealed less than 1 replication-competent adenovirus/10 7 PFU (20) . Selection of cells expressing the tetracycline-regulated transactivator. Three different selection schemes were used to facilitate the screening of stable cell lines expressing tTA. The 293-tTA cell line was obtained by cotransfection of calcium phosphate precipitates of the tTA expression and reporter plasmid ptTA-lux with the p3ЈSS plasmid (Stratagene), which allows for hygromycin resistance selection. The ptTA-lux plasmid contains the CMV promoter and tTA gene derived from pUHD15-1 (12) and the firefly luciferase gene under the control of the tTA-responsive promoter pCMV-1 derived from pUHC13-3 (12) . Individual clones resistant to hygromycin (450 g/ml) were subcultured into either tetracycline-free media or media containing 40 ng of anhydrotetracycline (Spectrum Chemical, Gardena, Calif.) per ml and screened for functional tTA expression 2 days later by assaying cell extracts for luciferase activity with the Promega luciferase assay system (Promega Corp., Madison, Wis.). An A549 cell line expressing tTA (A549-tTA) was generated by cotransfection of plasmid pUHD15-1 together with a plasmid that contains the SH-␤GAL gene under the control of the tTA-responsive promoter. This reporter plasmid, pTR/SH-␤GAL, was constructed by inserting the SH-␤GAL gene from plasmid pUT535 (Cayla, Toulouse, France) into the tTA-responsive expression vector pUHD10-3 (13) . The SH-␤GAL protein is a hybrid containing functional domains of the ␤-galactosidase and zeocin-phleomycin resistance proteins. A549 cells were transfected with calcium phosphate precipitates and selected for resistance to phleomycin at a dose of 30 g/ml. Resistant clones were tested for functional tTA activity by comparing the levels of expression of ␤-galactosidase in live cells that had been cultured in the presence of 5 g of tetracycline per ml or in tetracy- The expression cassettes are identical from the TATA box to the poly(A) site (pA), the main difference being upstream of the TATA box, where the tetracycline operator binding sequences (tetO) replace the CAAT box and the enhancer of the CMV major IE promoter. The diagrams are not drawn to scale. SS, splicing signal; SD, splice donor; SA, splice acceptor; tpl, tripartite leader; enh, enhancer; tet, tetracycline; Ori, origin of replication; pro, promoter. The expression cassettes contain two SDs as a result of the insertion of the MLP enhancer sequence into a small intron located downstream of the tpl in pAdBM1 (19) . The first SD is the one found after the third segment of the tpl, whereas the second SD is the one found after the first segment of the tpl and was added when the MLP enhancer mapping at ϩ30 to ϩ130 relative to the MLP transcription start site was cloned as a fragment of 108 nucleotides (23) .
cline-free medium by use of a flow cytometric ␤-galactosidase assay (8) . A HeLa S3 cell line expressing the reverse tTA protein was established by transfection with the rtTA expression vector pUHD172-1neo followed by selection in media containing G418 (13) . The resulting clones were screened by transient transfection with a tTA-regulated reporter plasmid pTR/GFP encoding the green fluorescence protein (GFP) as detailed previously (24) .
Protein extraction and analysis. For analysis of recombinant protein synthesis or accumulation, petri dishes of subconfluent cells at a density of 5.0 ϫ 10 5 cells/dish were infected with viral inocula corresponding to MOIs of 10 to 20 PFU/cell for 293 cells and 50 to 800 PFU/cell for A549 or HeLa S3 cells. At different times postinfection (p.i.), total protein extracts were prepared by lysing phosphate-buffered saline-washed cells with 2% sodium dodecyl sulfate (SDS) in 80 mM Tris-HCl (pH 6.8)-10% glycerol. Before protein analysis by SDS-polyacrylamide gel electrophoresis and Western blotting, performed as described previously (19) , the extracts were sonicated to shear the DNA. Quantification of the percentages of recombinant R1 and ⌬R1 in total protein extracts was done by densitometric scanning of the lanes of Coomassie blue-stained gels with a Jandel Scientific video analysis system as detailed previously (23) . Protein radiolabeling with [ 35 S]methionine was done as detailed previously (19) . Flow cytometry analysis of GFP expression. Exponentially growing cells (10 6 ) seeded in duplicate 60-mm plates were either infected with pAd5TR5GFP at increasing MOIs (A549-tTA cells) or coinfected with pAd5CMVtTA at 500 PFU/cell (HeLa S3 and A549 cells). After 40 h at 37°C with or without doxycycline (1 g/ml), the cells were fixed with 2% paraformaldehyde for 30 min at 4°C. GFP emission was analyzed with an EPICS XL-MCL flow cytofluorometer (Coulter, Miami, Fla.) equipped with a 15-mW argon ion laser and the following filters: 488-nm laser blocking, 488-nm long-pass dichroic, 550-nm long-pass dichroic, and 525-nm band-pass.
Ribonucleotide reductase assay. Ribonucleotide reductase activity of proteins R1 and ⌬R1 was measured in crude protein extracts obtained by 2 min of sonication followed by centrifugation at 12,000 ϫ g for 10 min at 4°C as previously detailed (23) .
RESULTS
Construction of the transfer vectors pAdTR5 and pAdCMV5.
We have been using the AES to produce sufficient amounts of HSV-2 R1 and R2 proteins for structural studies. Although the AES was very successful for the R2 protein, the R1 protein could not be obtained with a similar yield, partly due to poor solubility (23) . HSV-2 R1 is a more complex protein than cellular R1: it contains, in addition to a reductase domain, an amino-terminal domain of unknown function with an associated kinase activity (26) . Since the cellular R1 overexpressed with the AES was more soluble, we attempted to produce only the reductase domain of HSV-2 R1 by deleting the first 357 amino acids. Surprisingly, we were unable to generate an adenovirus recombinant expressing this ⌬R1 protein with vector pAdBM5, even after 10 carefully controlled transfections.
To overcome this problem, we constructed a new expression cassette, pAdTR5, hoping to be able to regulate the overexpression of the recombinant protein with the tetracycline-sensitive transactivator tTA (Fig. 1A) . The tetracycline-regulatable promoter in pAdTR5 is derived from the minimal CMV promoter (TATA box) fused to the tetO binding domain (Fig.  1B) . To ensure the highest possible level of expression upon induction, we cloned, downstream of the CMV TATA box, the adenovirus MLP tripartite leader sequence along with the MLP enhancer and splicing sequences, as found in pAdBM5 (23, 30) . For comparative purposes with a constitutive AdV, a similar CMV-based expression cassette, pAdCMV5, was also constructed. As shown in Fig. 1 , both expression cassettes are identical in sequence downstream from the TATA box up to the poly(A), the only differences lying in the absence of a CAAT box for pAdTR5 and in the upstream enhancer region.
Expression of HSV-2 R1 in pAdTR5-and pAdCMV5-derived recombinants. The performance of our new vectors was first assessed with the HSV-2 R1 gene by producing the adenovirus recombinants Ad5TR5R1 and Ad5CMV5R1. Our best previously produced adenovirus recombinant for the R1 gene, Ad5BM5R1, yielded in permissive 293 cells R1 levels exceeding 20% TCP (more than 60 g/10 6 cells) (23) . To complement the tetracycline-regulated expression cassette, stable clones expressing tTA or rtTA were derived from 293S (24), A549, and HeLa S3 cells as described in Materials and Methods. With a tetracycline-regulated reporter gene, the cell lines used in this study were further selected for their ability to retain, in the absence of selective pressure, both high and inducible levels of expression.
The amounts of R1 protein accumulated in nonpermissive A549-tTA and HeLa-rtTA cells at 48 h p.i. with increasing MOIs of Ad5CMV5R1 and Ad5TR5R1 are shown on Coomassie blue-stained gels in Fig. 2A and B. Ad5CMV5R1 yielded, with both cell lines, maximal levels of R1 at 800 PFU/cell ( Fig. 2A and B, lanes 6 ), the highest MOI tested (25 to 30% TPC), and low levels of expression at an MOI of 50 (lanes 2). Somewhat higher levels of expression were achieved in HeLartTA cells than in A549-tTA cells. With Ad5TR5R1, maximal levels of R1 expression were obtained at an MOI of 50 to 100 in both A549-tTA and HeLa-rtTA cells ( Fig. 2A and B, lanes 7 to 11). Although the Ad5TR5R1 vector did not achieve the level of R1 production that could be obtained with the Ad5CMV5R1 vector at very high MOIs, it achieved a level of expression that approached 20% TCP. Furthermore, at lower MOIs (Ͻ50), Ad5TR5R1 was about 10-fold more efficient than Ad5CMV5R1; for example, an MOI of 5 with Ad5TR5R1 produced a substantial R1 level corresponding to 4% TCP (data not shown).
Regulation of gene expression by an AdV recombinant expressing the tTA protein. To increase the range of cell lines that could be efficiently transduced by our pAdTR5 cassette, we also constructed an AdV recombinant that could express the tTA protein under the control of the CMV promoter. In addition, as the high level of protein expression obtained in Ad5TR5R1-infected tTA cells was found to be dependent on the tTA clones used (data not shown), we hoped that higher levels of tTA could be expressed by AdV transduction than by our best stable clones and that this expression would further increase the production of R1 in Ad5TR5R1-infected cells. To determine the conditions for optimal gene expression with the tetracycline-regulatable expression system, we used AdTR5GFP, an adenovirus recombinant expressing the jel- a The number of transduced cells was Ͼ98% in the absence of doxycycline at every MOI. FI, fluorescence index calculated as the percentage of cells expressing GFP by the mean fluorescence value; ON, GFP expression without doxycycline; OFF, GFP expression with 1 g of doxycycline per ml; IND, induction factor calculated as the ratio between the FI of the ON state and the basal FI; EXT, extinction factor calculated as the ratio between the FI of the ON state and the FI of the OFF state. lyfish GFP which is easily quantifiable by cytofluorometry (24) . When A549 and HeLa S3 cells were coinfected with AdTR5GFP at an MOI of 50 and AdCMVtTA at increasing MOIs, we observed an increase in GFP expression that was approximately proportional to the MOI up to 500, where it plateaued (data not shown). With AdCMVtTA at this optimal MOI of 500, A549, A549-tTA, HeLa S3, and HeLa-rtTA cells were coinfected with Ad5TR5R1 at MOIs of 50, 100, and 400, and R1 accumulation was examined by SDS-polyacrylamide gel electrophoresis at 48 h p.i. As shown in Fig. 2C and D, the coinfection yielded, in A549 cells, slightly higher levels of R1 than the infection of A549-tTA cells with Ad5TR5R1 alone (compare lane 6 with lane 9 in Fig. 2C ) and equivalent levels in HeLa-rtTA cells (compare lane 6 with lane 9 in Fig. 2D ). In another experiment, at least a twofold-higher level of recombinant protein expression was measured following coinfection of A549 cells with Ad5CMVtTA and Ad5TR5GFP than following single infection of A549-tTA cells with Ad5TR5GFP (data not shown). Interestingly, infection with Ad5TR5R1 or Ad5CMVtTA alone did not produce the appearance of any new protein band detectable by Coomassie blue staining (Fig.  2C and D, lanes 3 and 4 and data not shown) . This result indicated that, although being driven from a CMV-based promoter cassette, tTA was expressed at a much lower level than R1 and that R1 expression with the tetracycline-regulated promoter was very low in the absence of tTA. Altogether, these results showed not only that the tTA protein can be transduced by an adenovirus recombinant but also that in this way the transactivator appears to be produced in higher effective amounts than by the best stable cell lines.
Overexpression of the cytotoxic ⌬R1 protein. As mentioned above, the cytotoxic nature of ⌬R1 was initially suspected from our inability to generate a recombinant adenovirus expressing the deletion protein in several transfection experiments regardless of whether the pAdBM5 or pAdCMV5 vector was used. However, when the pAdTR5 vector was used, Ad5TR5⌬R1, a recombinant adenovirus expressing R1(⌬2-357), was readily obtained in the first attempt. An initial analysis of ⌬R1 expression in permissive 293-tTA cells infected with Ad5TR5⌬R1 for 48 h indicated that the level of ⌬R1 accumulation was lower (10% TCP) than that of the full-length R1 in cells infected with either Ad5CMV5R1 or Ad5TR5R1 (20 to 25% TCP) (Fig. 3, compare lane 6 with lanes 2 and 4) . Moreover, whereas in cells infected with Ad5TR5⌬R1 the accumulation of several viral polypeptides, including the hexon and 100K protein, was severely reduced (Fig. 3, 5 and 6), their accumulation was not compromised by the presence of a higher amount of full-length R1 in cells infected with Ad5TR5R1 (Fig. 3, compare lanes 2, 3, and 4) . The reduction in the synthesis of viral polypeptides might explain why we were unable to generate a recombinant virus for ⌬R1 with a constitutive expression cassette. Consistent with this idea, the titer of Ad5TR5⌬R1 grown on 293-tTA cells under induced conditions (in the absence of anhydrotetracycline) was 20-fold lower than when the expression of ⌬R1 was repressed (data not shown). The experiment presented in Fig. 3 also shows that the expression of R1 or ⌬R1 could be repressed about 25-fold by the addition of 40 ng of anhydrotetracycline per ml (compare lanes 3 and 5 with lanes 4 and 6) . Repression was not complete, likely due to low-level transactivation of the minimal TATA box by adenovirus E1 proteins (17, 39) in combination with the high copy number of the viral vector following replication in permissive 293 cells. The extent of repression that could be achieved by this system was quantified more precisely with Ad5TR5GFP and nonpermissive A549-tTA cells. As can be seen in Table 1 , it was greater than 50-fold at MOIs of 50 to 250 PFU/cell. Interestingly, at the highest MOI, the extinction factor was decreased to a value of 28, which corresponds to the repression observed in permissive 293 cells. The nearly linear relationship between the MOI of AdTR5GFP and the basal expression level indicates that the copy number of the tetracycline-regulated expression cassette is the most important factor which determines the basal expression level (Table 1) .
To avoid the cytopathic effects associated with adenovirus replication, we used nonpermissive cells to further examine the cytotoxic nature of the ⌬R1 protein. The marked cytotoxicity of ⌬R1 in A549-tTA and HeLa-rtTA cells infected with Ad5TR5⌬R1 was evidenced by drastic morphological cellular changes and a gradual decline in attached cell numbers, as exemplified in Fig. 4 for A549-tTA cells. The first signs of a cytopathic effect could be seen by 5 h p.i., when cytoplasmic blebbing appeared in about 5% of the Ad5TR5⌬R1-infected cells. Blebbing was soon followed by cell rounding and detachment. By 12 h p.i., approximately 15 to 20% of the Ad5TR5⌬R1-infected cells appeared to be floating in the medium (Fig. 4A, bottom left panel) . By 48 h p.i., about half of the input cells remained attached to the culture flask, and these cells were enlarged in size and granular in appearance (Fig.  4A, bottom right panel) . There was no apparent sign of cytotoxicity in Ad5TR5R1-infected cells (Fig. 4A, top panels) or in cells infected with Ad5TR5⌬R1 in the presence of anhydrotetracycline (data not shown). Whereas cell numbers increased in both mock-infected cells and cells infected with Ad5TR5R1, proliferation of the Ad5TR5⌬R1-infected cells did not occur and the numbers of attached cells gradually declined to a level, at 55 h p.i., approximately 60% of the starting cell density (Fig.  4B ). Cells infected with Ad5TR5⌬R1 in the presence of anhydrotetracycline initially grew, and after 30 h, the cell numbers plateaued in a manner similar to that of Ad5TR5R1-infected cells (Fig. 4B) , demonstrating that the accumulation of the ⌬R1 protein brings about the demise of Ad5TR5⌬R1-infected cells.
In infected A549-tTA cells, the ⌬R1 protein accumulated to a level of about 10% TCP, like 293-tTA cells (data not shown). To determine whether the lower level of ⌬R1 accumulation was related directly to a lower rate of synthesis or indirectly to its cell-killing effect, we analyzed the rates of synthesis of R1 and ⌬R1 at various times p.i. by [ 35 S]methionine pulselabeling of A549-tTA cells infected with either Ad5TR5R1 or Ad5TR5⌬R1 at an MOI of 100 (Fig. 5) . The synthesis of both R1 and ⌬R1 proteins, which were detectable in total cell extracts as early as 2 h p.i., occurred at similar rates until 6 h. However, between 6 and 24 h p.i., the synthesis of the fulllength R1 protein exceeded that of the ⌬R1 protein (Fig. 5,  compare lanes 3 and 4 with lanes 7 and 8) . Beyond 24 h, the synthesis of the ⌬R1 protein as well as other cellular proteins decreased dramatically, whereas in Ad5TR5R1-infected cells, the synthesis of the R1 protein remained elevated, like general protein synthesis, up to 72 h p.i. (data not shown). General protein synthesis was also not impaired in the presence of anhydrotetracycline at a dose that completely repressed ⌬R1 protein synthesis in A549-tTA cells infected with Ad5TR5⌬R1 (Fig. 5, lane 9) or R1 protein synthesis in AdTR5R1-infected cells (Fig. 5, lane 5) . As the initial rates of synthesis of both proteins were similar, it appears more likely that the lower level of ⌬R1 accumulation was an indirect effect of its toxicity.
Lastly, we examined if our initial objective of obtaining a more soluble protein had been attained by evaluating the solubility of R1 and ⌬R1 proteins accumulated in total cell extracts. Unfortunately, the ⌬R1 protein was somewhat less soluble (15% solubility) than our reference full-length R1 protein produced in 293 cells infected with Ad5BM5R1 (30% solubility). Nevertheless, the intrinsic activity of the ⌬R1 protein present in the soluble fraction, as measured by an in vitro ribonucleotide reductase assay, was similar to that of the R1 protein, indicating that the first 357 amino acids of the protein were not essential to its reductase activity (data not shown). Interestingly, the full-length R1 protein produced in A549-tTA cells infected with Ad5TR5R1 exhibited nearly twofold more solubility than our reference R1 protein.
DISCUSSION
The pAdTR5 and pAdCMV5 transfer vectors significantly improved the utility of AdV for high-level transgene expression in mammalian cells. First, each of these vectors allowed for very high levels of recombinant protein production in nonpermissive cell lines. This fact greatly simplified the production and purification effort, since the recombinant protein could be produced at levels approaching 15 to 25% TCP in the absence of the synthesis of other viral proteins. Second, by incorporation of the tetracycline-regulated promoter into the expression vector, it was possible to use the AES to produce toxic proteins that interfered with adenovirus replication at levels approaching those which can be achieved by use of a constitutive expression cassette.
In comparison with the pAdTR5 and pAdCMV5 transfer vectors, adenovirus MLP-based expression cassettes such as pAdBM5-derived AdV, which yielded the best protein production levels in permissive 293 cells (23) , typically yielded, at equivalent MOIs, three-to fivefold-lower expression levels in nonpermissive cells, depending on the transgene tested (unpublished results). This observation is consistent with previous reports showing that adenovirus MLP-based expression cassettes, even when modified with additional enhancer sequences, are less efficient than CMV promoter-based expression cassettes in most nonpermissive cell lines (38, 40) . Although the relative contributions of the various elements cloned downstream of the CMV TATA box to the improvement in transgene expression in AdV were not systematically assessed, we suspect that in nonpermissive cells the most significant cis-acting elements are the adenovirus tripartite leader and splice sites. In fact, the adenovirus major late enhancer is not likely to be active in the absence of viral protein IVa2, which is normally expressed after DNA replication begins (21) ; even at a high MOI in A549 or HeLa cells, we did not find evidence that the adenovirus late proteins were expressed at significant levels, suggesting that levels of IVa2 were minimal. Nevertheless, the adenovirus major late enhancer was included in the expression cassette both to take advantage of its activity in permissive 293 cells and also to obtain a direct comparison with pAdBM5, our best-characterized transfer vector (23) .
The high level of expression attained in nonpermissive cell lines with our new vectors is substantially greater than the previously reported expression levels of about 2% TCP obtained with nonoptimized CMV promoter-based expression cassettes (1, 18, 25, 37, 38, 40; unpublished results) . The exception is a study by Wilkinson and Akrigg in which an expression level in the range of 20% TPC was obtained in MRC5 cells infected with an AdV expressing the E. coli lacZ gene (37). However, this high level of expression of ␤-galactosidase required the addition of forskolin, which stimulated the CMV promoter more than 10-fold. Furthermore, overexpression of ␤-galactosidase was obtained only after 144 h p.i.; at 48 h p.i., a time corresponding to the peak of expression with our optimized expression cassettes, the expression of ␤-galactosidase was fivefold lower.
We used the tetracycline-regulatable adenovirus cassette to produce, at high levels, a protein that was suspected to be cytotoxic, and we confirmed the cytotoxic nature of the ⌬R1 protein by showing that infection of A549-tTA cells with the Ad5TR5⌬R1 vector brought about an eventual demise of the infected cells. The cytotoxicity of the ⌬R1 protein was totally unexpected. Although we do not have any clues to explain it at this point, it is evident that overexpression per se was not the cause, since the R1 protein was expressed at even higher levels. Furthermore, preliminary experiments indicated that cytotoxicity could be observed at levels lower than 0.01% TCP (19a) . This cytotoxic effect and the synthesis of the ⌬R1 protein could be nearly completely abrogated by inhibition of the activity of the tTA protein with anhydrotetracycline in Ad5TR5⌬R1-infected cells.
We have also generated a number of other recombinant adenovirus using the pAdTR5 vector. The vector has made it possible to overexpress, at more than 10% TCP, the human enzyme methenyltetrahydrofolate synthetase, the heat-inducible chaperone protein hsp70, the adenovirus E1B-19K protein, and the viral protein encoded by ORF5 of the porcine reproductive and respiratory syndrome virus (unpublished data). This last protein was recently shown to induce apoptosis when expressed in BSC40 cells with the T7 vaccinia virus system (32) . We have also shown that the expression of ⌬R1 by infection with Ad5TR5⌬R1 induces the death of A549 and HeLa S3 cells by an apoptotic process (19a) . The characterization of the apoptotic behavior of ⌬R1 or any other proteins with similar behavior will be facilitated by the use of an expression system allowing for the tight regulation of gene expression in the absence of any other toxic effects resulting from the infection of permissive cells, such as is the case with vaccinia virus vectors. Curiously, the adenovirus E1B-19K protein, which exhibited potent antiapoptotic activity in both adenovirus-infected cells and stable cell lines (35; reviewed in reference 33), could be overexpressed only with the pAdTR5 vector. We found that at high MOIs in nonpermissive cells, the overexpression of E1B-19K (Ͼ2% TPC) was very toxic, killing the cells by necrosis (unpublished results).
Another elegant molecular switch, based on the Cre-loxP recombination system, has been described for the regulation of gene expression in AdV (3) . With this system, the transgene is placed under the control of a strong constitutive promoter, such as the CMV promoter, and its expression is silenced by the inclusion of a spacer fragment of 1.3 kbp between the promoter and the open reading frame. This spacer fragment is flanked by two lox sites, upon which the Cre recombinase acts to precisely excise it, thereby restoring efficient expression of the transgene. Although this vector system has the potential of expressing toxic gene products in AdV, overexpression of toxic proteins has not been reported thus far with it. Furthermore, the Cre-loxP system is less flexible than the tetracycline-regulated gene switch described here in two respects. First, the need for a spacer fragment larger than 1 kbp limits the available space for the cloning of transgenes into AdV, thereby reducing the option for cloning large cDNAs or constructing AdV with double expression cassettes (6) . Second, since it is not possible to regulate the Cre recombination switch with chemical inducers, one is restricted to the scenario of coinfection with two viruses instead of being able to combine the transactivator with the inducible expression cassette in one virus, as we are currently doing with the tetracycline-regulated gene switch. This latter approach was reported to be more efficient for the generation of transgenic animals with regulated transgene expression (29) and should prove to be equally efficient for gene transfer experiments with AdV.
Finally, in addition to the application of the AES to protein production in animal cell cultures, the pAdCMV5 and pAd5TR5 vectors will be useful for functional studies and gene therapy applications. Adenoviruses are already well established as effective vectors for human gene therapy applications. The higher level of expression that can be achieved with these AdV in nonpermissive cells will make it possible to express transgenes at significant levels in vivo at lower MOIs, thereby allowing minimization of the toxic side effects associated with the load of adenovirus particles. For example, Connelly et al. recently reported that a threefold improvement in the level of expression of blood coagulation factor VIII following AdV transduction allowed for the injection of significantly lower vector doses while still providing factor VIII at therapeutic levels (7) . Furthermore, the tTA system has been shown to be highly effective for the regulated expression of recombinant proteins in transgenic animals (29) . The tetracycline-regulated AES that we have described here will make it possible to express in vivo by coinfection with an AdV expressing tTA a therapeutic protein at levels that can be precisely regulated by the in vivo concentration of the effector molecule tetracycline. We are currently assessing the usefulness of such an inducible vector for in vivo gene transfer experiments.
